Article
Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 31 Dec 2023
Sun Shan-Liang, Wu Jia-Zhen, Wang Jing-Jing, Zhou Hai, Zhang Chen-Qian, Tong Zhen-Jiang, Wang Yi-Bo, Sha Jiu-Kai, Wang Qing-Xin, Liu Jia-Chuan, Zheng Xin-Rui, Li Qing-Qing, Zhang Meng-Yuan, Yang Jin, Wei Tian-Hua, Wang Zi-Xuan, Yu Yan-Cheng, Ding Ning, Leng Xue-Jiao, Xue Xin, Li He-Min, Dai Wei-Chen, Yin Xiao-Ying, Yang Ye, Duan Jin-Ao, Li Nian-Guang, Shi Zhi-Hao
Abstract excerpt
The therapeutic benefits of available FLT3 inhibitors for AML are limited by drug resistance, which is related to mutations, as well toxicity caused by off-target effects. In this study, we introduce a new small molecule FLT3 inhibitor called danatinib, which was designed to overcome the limitations of currently approved agents. Danatinib demonstrated greater potency and selectivity, resulting in cytotoxic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.